Director, Oncology Early Translational Biomarkers

Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success.

We’re uniting science, technology, and talent to get ahead of disease together.

Find out more:

Our approach to R&DFor candidates seeking to be located at our Stevenage site, this role will temporarily be based ever, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029.Director,

Oncology Early Translational Biomarkers Are you an experienced leader in Oncology Translational Medicine (OTM) looking to be part of an innovative, dynamic and growing organization? Do you thrive at the intersection of biomarker strategy, early clinical development and mechanistic research across multiple therapeutic modalities? If so, this Director, Oncology Early Translational Biomarkers is an exciting opportunity to explore.

GSK Oncology has a rapidly growing and diverse pipeline spanning novel small molecules, first- and best-in-class large molecules, and cutting-edge therapies, the opportunity to shape translational strategy across our early Oncology programs represents a rare and exciting career opportunity. You will partner with world-class scientists, clinicians, and KOLs—making decisions that directly impact patients with cancer.

Job Purpose:

The Director , Oncology Early Translational Biomarkers is accountable  for the definition and implementation of a translational biomarker strategy and delivery across a expanding early oncology  portfolio of spanning both small and large molecules, novel modalities and immune cell engagers. The Early Translational Biomarkers team provides end-to-end translational medicine support from development and integration of biomarker strategies, assay development and technical validation through clinical deployment and data interpretation across early-phase proof of concept studies.

You will be the scientific and operational owner of translational medicine strategy for the early Oncology portfolio, embedded as the dedicated translational lead across program teams. You will deliver biomarker and translational strategies from preclinical through Phase 1. The role covers a wide range of therapeutic modalities requiring deep disease biology expertise, versatile biomarker and assay knowledge alongside experience in clinical implementation.

The role partners closely with Oncology Research Unit, Discovery, Innovative Biological Model Systems, Clinical Development and Oncology Tumour teams, Clinical Operations, Diagnostics, Biomarker Operations and external partners to ensure translational readiness, de-risk clinical entry and accelerate go/no-go decisions.

Key Responsibilities:

Act as the translational medicine lead for assigned early Oncology programs (preclinical to Phase
1): define and own biomarker and translational strategies, plans and decision-enabling datasets.

Identify cutting edge science and technological advances and incorporate them into biomarker strategies to guide indication selection, patient enrichment, and combination strategies.

Develop program-specific translational plans including…